Seek Returns logo

ALHC vs. CYTK: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ALHC and CYTK, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

With ALHC at 3.03 billion USD and CYTK at 3.74 billion USD, their market capitalizations sit in the same ballpark.

ALHC’s beta of 1.33 points to much larger expected swings compared to CYTK’s calmer 0.81, suggesting both higher upside and downside potential.

SymbolALHCCYTK
Company NameAlignment Healthcare, Inc.Cytokinetics, Incorporated
CountryUSUS
SectorHealthcareHealthcare
IndustryMedical - Healthcare PlansBiotechnology
CEOMr. John E. KaoMr. Robert I. Blum
Price15.33 USD31.31 USD
Market Cap3.03 billion USD3.74 billion USD
Beta1.330.81
ExchangeNASDAQNASDAQ
IPO DateMarch 26, 2021April 30, 2004
ADRNoNo

Performance Comparison

This chart compares the performance of ALHC and CYTK over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ALHC and CYTK based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • Neither ALHC nor CYTK turned a profit—both carry negative P/E ratios of -32.75 and -6.03, underscoring continued losses that pressure their valuations.
  • ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas CYTK at 10.57 has projections for stable or growing earnings.
  • CYTK carries a sub-zero price-to-book ratio of -13.93, indicating negative equity. In contrast, ALHC (P/B 27.45) has positive book value.
  • CYTK reports a negative Price-to-Free Cash Flow ratio of -9.14, showing a cash flow shortfall that could threaten its operational sustainability, while ALHC at 159.00 maintains positive cash flow.
SymbolALHCCYTK
Price-to-Earnings Ratio (P/E, TTM)-32.75-6.03
Forward PEG Ratio (TTM)-1.1110.57
Price-to-Sales Ratio (P/S, TTM)1.01194.57
Price-to-Book Ratio (P/B, TTM)27.45-13.93
Price-to-Free Cash Flow Ratio (P/FCF, TTM)159.00-9.14
EV-to-EBITDA (TTM)-64.47-8.64
EV-to-Sales (TTM)0.86231.90
EV-to-Free Cash Flow (TTM)136.01-10.89

Dividend Comparison

Neither ALHC nor CYTK currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.

SymbolALHCCYTK
Dividend Yield (TTM)0.00%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ALHC and CYTK, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • CYTK has negative equity (debt-to-equity ratio -2.97), suggesting asset shortfalls, whereas ALHC at 0.07 preserves healthier equity coverage.
  • Both ALHC and CYTK report negative interest coverage ratios (-2.98, -6.14), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
SymbolALHCCYTK
Current Ratio (TTM)1.695.99
Quick Ratio (TTM)1.695.99
Debt-to-Equity Ratio (TTM)0.07-2.97
Debt-to-Assets Ratio (TTM)0.010.63
Interest Coverage Ratio (TTM)-2.98-6.14